Clinical Scorecard: Expanding the Understanding of the Link Between Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: Addressing Metabolic Risks Beyond Genetic Factors
At a Glance
Category
Detail
Condition
Non-Alcoholic Fatty Liver Disease (NAFLD) and Coronary Artery Disease (CAD)
Key Mechanisms
Metabolic dysfunction including insulin resistance, obesity, dyslipidaemia, pro-inflammatory status, and oxidative stress linking NAFLD and CAD
Target Population
Patients with liver steatosis and metabolic risk factors, including those with MASLD
Care Setting
Cardiovascular and metabolic disease management settings, including primary and specialized care
Key Highlights
No causal genetic association found between NAFLD and coronary artery calcification (CAC) based on Mendelian randomization analysis.
NAFLD is better interpreted as a hepatic manifestation of systemic metabolic dysfunction rather than a direct cause of CAC.
Advanced NAFLD stages with hepatic fibrosis are more strongly associated with pro-inflammatory cytokines and increased cardiovascular risk.
Guideline-Based Recommendations
Diagnosis
Use broader MASLD criteria including metabolic risk factors without requiring liver biopsy.
Assess presence of liver fibrosis to identify advanced disease stages linked to higher cardiovascular risk.
Management
Focus on comprehensive evaluation and management of metabolic risk factors such as insulin resistance, obesity, and dyslipidaemia.
Implement early lifestyle interventions and management of comorbidities to reduce cardiovascular risk.
Monitoring & Follow-up
Monitor progression of liver fibrosis and metabolic parameters to identify patients at increased risk of cardiovascular events.
Evaluate coronary artery calcification progression in patients with advanced liver disease.
Risks
Recognize that advanced NAFLD with fibrosis increases pro-inflammatory cytokines (e.g., TNF-α, IL-6) and oxidative stress, elevating cardiovascular risk.
Consider social determinants of health as factors influencing disease outcomes and access to care.
Patient & Prescribing Data
Patients with fatty liver disease and metabolic dysfunction at risk for cardiovascular disease
Treatment should target modifiable metabolic risk factors and lifestyle changes rather than focusing solely on liver disease; addressing social determinants is critical for equitable care.
Clinical Best Practices
Interpret NAFLD as a marker of systemic metabolic dysfunction requiring holistic cardiovascular risk assessment.
Prioritize early intervention on lifestyle and metabolic comorbidities to prevent progression of both liver and cardiovascular disease.
Incorporate evaluation of social determinants of health into patient care plans to optimize outcomes.
Focus research on patients with advanced liver fibrosis to clarify independent cardiovascular risks.
A four-factor staging system stratified response rates from 90.9% to 37.5% in a retrospective cohort study, although the model showed only moderate discrimination (C statistic, 0.68) and requires external validation
